Newsroom

MedinCell’s partner Teva announces successful launch of UZEDY™

August 2, 2023

August 2, 2023

MedinCell has received the last tranche of €10m from the European Investment Bank (EIB) loan

July 31, 2023

July 31, 2023

MedinCell announces the availability of its 2022-23 Universal Registration Document including the Annual Financial Report

July 31, 2023

July 31, 2023

MedinCell announces its full year financial results April 2022 – March 2023

June 26, 2023

June 26, 2023

Videoconference • Annual Results

June 26, 2023

MedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023

June 5, 2023

June 5, 2023

Dr Grace Kim, recognised specialist in financial strategy and investor relations in the biopharmaceutical sector

May 31, 2023

Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile

May 22, 2023

May 22, 2023

MedinCell announces the successful pricing of its Global Offering and raises €25 million

May 12, 2023

May 12, 2023

MedinCell launches a Global Offering for approximately 25 million euros

May 11, 2023

May 11, 2023

MedinCell: mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)

May 4, 2023

May 4, 2023

First FDA approval and US commercial launch, MedinCell enters new era

May 2, 2023

May 2, 2023